Constance Scharff | Cliffside Malibu
The pharmaceutical industry has provided the world with incredible medical breakthroughs. Because of Salk’s (and Sabin’s) research and generosity, polio no longer ravages bodies or brings fear to communities. Diabetes can be managed with a number of products, giving diabetics a higher quality of life than ever before. With the birth control pill, women can effectively plan the size of their families and for many, gain relief from menstrual cycles that are unregulated, abnormally heavy, or painful. From your place in a pharmaceutical company, you are uniquely positioned to change the world in positive ways, to improve the lives of millions, known and unknown to you. It is a tremendous opportunity to be an actor for good.
Continue reading "You’re Killing Us and it Has to Stop"
In The Headlines
Wendy Goldstein | Cooley, LLP
Although science continues to outpace the law, it is imperative that compliance infrastructures remain current. Effective compliance programs continue to be top of mind for industry stakeholders. Investors, elected officials, enforcement authorities, government and private payors, and employees themselves continue to demand responsible corporate behavior from health care and life sciences companies, management and directors. Whether large cap or small cap; traded on a public market or held privately; involved with a significant sized product portfolio or focused on a small number of products; U.S. domiciled or foreign-based, those participating in the industry continue to ask tough questions about the compliance culture and the “tone at the top” of these organizations. In 2015, there were several long-awaited settlements of multi-year false claims act government investigations and other judicial decisions. These included Novartis Pharmaceuticals, Genzyme Corporation and Warner Chilcott settlements; as well as the Amarin Pharmaceuticals Ltd. and Pacira Pharmaceuticals, Inc. decisions. Such developments should be used by life science companies to update and assess the effectiveness of their respective corporate compliance programs in 2016. Three key compliance areas to remain focused in 2016 are discussed below.
Continue reading "Insight: Life Sciences Compliance Considerations for 2016"
Topic of Discussion
Rachel Daricek | Aptus Health
How pharma marketers can make this the year be more efficient with multi-channel MLR submissions, go mobile, and leverage vendor partners to the fullest – all with the end goal of better engaging targets while complying with FDA marketing requirements
Continue reading "Three Smart Multi-Channel Marketing Resolutions for 2016"
East Norriton, Penn. Feb. 4, 2016. TGaS® Advisors is expanding its roster of commercial solutions with the addition of Medical Regulatory Legal (MRL) Operations. The new solution reflects high client demand in this critical area. The benchmarking and advisory firm also named TGaS Management Advisor Karl Kraft to head the new practice. The MRL benchmark is in growing demand as companies seek to make this critical process shorter, more efficient, more strategic and less costly, according to ... [Continue Reading]
A UL EduNeering Sponsored Article The whitepaper for this article is available for free download here: “Top Seven Risks to Consider When Selecting a Life Science LMS”. Scott Barnard | UL EduNeering/UL Life & Health Life Science companies operate in a highly regulated industry. With risk mitigation core to their DNA, they must be careful when evaluating an enterprise Learning Management System (LMS) or a Talent Management System (TMS) used in GxP areas. It is critical that these systems ... [Continue Reading]